Acasti Pharma (TSXV:ACST) ROCE % : -16.03% (As of Dec. 2023)

View and export this data going back to 2011. Start your Free Trial

What is Acasti Pharma ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Acasti Pharma's annualized ROCE % for the quarter that ended in Dec. 2023 was -16.03%.

Acasti Pharma ROCE % Historical Data

The historical data trend for Acasti Pharma's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Acasti Pharma ROCE % Chart

Acasti Pharma Annual Data

Trend

Feb13

Feb14

Feb15

Feb16

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

ROCE %

Get a 7-Day Free Trial

-220.79

-134.01

-27.46

-16.51

-19.04

Acasti Pharma Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
ROCE %	Get a 7-Day Free Trial															-14.87	-17.70	-15.94	-11.42	-16.03

Acasti Pharma ROCE % Calculation

Acasti Pharma's annualized ROCE % for the fiscal year that ended in Mar. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Mar. 2023 )		(A: Mar. 2022 )		(A: Mar. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Mar. 2023 )		(A: Mar. 2022 )		(A: Mar. 2023 )
	=	-24.967	/	( ( (162.833 - 4.127)	+	(108.264 - 4.667) )	/ 2 )
	=	-24.967	/	( (158.706	+	103.597)	/ 2 )
	=	-24.967	/	131.1515
	=	-19.04 %

Acasti Pharma's ROCE % of for the quarter that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Dec. 2023 )		(Q: Sep. 2023 )		(Q: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Dec. 2023 )		(Q: Sep. 2023 )		(Q: Dec. 2023 )
	=	-16.328	/	( ( (105.826 - 1.89)	+	(102.21 - 2.375) )	/ 2 )
	=	-16.328	/	( ( 103.936	+	99.835 )	/ 2 )
	=	-16.328	/	101.8855
	=	-16.03 %

(1) Note: The EBIT data used here is four times the quarterly (Dec. 2023) EBIT data.

Acasti Pharma (TSXV:ACST) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Acasti Pharma ROCE % Related Terms

Thank you for viewing the detailed overview of Acasti Pharma's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Acasti Pharma (TSXV:ACST) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Acasti Pharma Inc (TSXV:ACST) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

ACST:USA A1P0:Germany

Address

3009 Boulevard de la Concorde East, Suite 102, Laval, QC, CAN, H7E 2B5

Website

https://www.acastipharma.com

Acasti Pharma Inc is a late-stage specialty pharma company with drug delivery technologies and drug candidates addressing rare and orphan diseases. Its novel drug delivery technologies have the potential to improve the performance of marketed drugs by achieving faster onset of action, enhanced efficacy, reduced side effects, and more convenient drug delivery all of which could help to increase treatment compliance and improve patient outcomes.